Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BNTC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $285.88M
- EPS (TTM)
- -$1.02
- Dividend yield
- None
- Ex-dividend date
- Jun 1, 2018
- 52-week range
- 7.72 – 14.39
- Day range
- 7.75 – 8.16
- Volume / Avg
- 268.68K / 174.01K
- Beta
- —
- Shares outstanding
- 36.12M
52-week range
BNTC stock today
Shares of Benitec Biopharma (BNTC) finished lower on Nov 20 at $7.92, a drop of 2.76% or $0.225 per share, versus the S&P 500's 3.70% decline. Shares are 45.0% below their 52-week high of $14.39, set on Dec 31, 2025 and 2.5% above the 52-week low of $7.72, near the bottom of the past year's range. BNTC is down 41.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 40.3%.
Benitec Biopharma has posted a net loss over the last twelve months (EPS of -$1.02), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Benitec Biopharma
Company profileBenitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jerel A. Banks M.D., Ph.D.
- Headquarters
- Hayward, CA
- Employees
- 24
- IPO year
- 2015
- Website
- benitec.com
Financial highlights
Full financialsBenitec Biopharma reported a net loss of $45.5 million, compared with a loss of $37.9 million a year earlier. Diluted earnings per share came in at -$0.98.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $75.00K | $73.00K |
| Growth | — | — | -100.00% | +2.74% | +23.73% |
| Net income | $-45.55M | $-37.92M | $-21.75M | $-19.56M | $-18.21M |
| EPS (diluted) | $-0.98 | $-1.05 | $-1.22 | $-14.12 | $-37.88 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$23.75+200.06%
- Strong buy 2
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.26 vs $-0.30
- Surprise
- +13.33%
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $0.765
- Ex-dividend date
- Jun 1, 2018
BNTC news
All BNTC news- UPDATED -- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational UpdateGlobeNewswire
- Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational UpdateGlobeNewswire
- Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike DealsNasdaqAARD, ABBV, ARTV, AZN
- Benitec Biopharma Inc. Announces Positive Interim Phase 1b/2a Results for High Dose BB-301Nasdaq
Benitec Biopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GLSIGreenwich LifeSciences Inc. | 19.25 | -2.73% | $282.56M | vs BNTC |
| FULCFulcrum Therapeutics Inc. | 3.69 | -0.54% | $281.85M | vs BNTC |
| EVMNEvommune Inc. | 7.04 | -2.76% | $291.10M | vs BNTC |
| RLMDRelmada Therapeutics Inc. | 2.62 | -15.76% | $279.54M | vs BNTC |
| SPRYARS Pharmaceuticals Inc. | 2.96 | -11.90% | $297.56M | vs BNTC |
| GALTGalectin Therapeutics Inc. | 2.69 | -4.27% | $271.35M | vs BNTC |
| VCREVicore Pharma Holding AB ADR | 9.41 | -5.09% | $264.89M | vs BNTC |
| EBSEmergent BioSolutions Inc. | 5.05 | -1.94% | $259.65M | vs BNTC |
Indexes, lists and sector
Benitec Biopharma stock FAQ
What is Benitec Biopharma's stock price today?
BNTC last traded at $7.92 as of Nov 20, 4:00 PM EST, down 2.76% on the day. Prices are delayed at least 15 minutes.
Does Benitec Biopharma pay a dividend?
Yes. Benitec Biopharma pays $0.00 per share annually. The most recent dividend of $0.765 had an ex-dividend date of Jun 1, 2018.
Who is Benitec Biopharma's CEO?
Dr. Jerel A. Banks M.D., Ph.D. is the chief executive officer of Benitec Biopharma Inc., which has about 24 employees.
Has BNTC ever split its stock?
Yes. The most recent BNTC stock split was a 1-for-17 split on Jul 26, 2023, one of 4 splits on record.
What is the BNTC 52-week high?
The 52-week high for BNTC is $14.39 and the 52-week low is $7.72. The stock is currently 45.0% below its high.